NPM1 and acute myeloid leukemia: Recent studies concerning adult AML showed increased responses to VTX amongst NPM1- [29,76,77,78], IDH1/2-, TET2-, and relapsed or refractory RUNX1-mutated patients, compared to the other cases [77,78].